Lymphatic vessel activation in cancer

被引:50
作者
Das, Suvendu [1 ]
Skobe, Mihaela [1 ]
机构
[1] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
来源
LYMPHATIC CONTINUUM REVISITED | 2008年 / 1131卷
关键词
lymphangiogenesis; lymphatic endothelium; lymphatic metastasis; sentinel lymph node biopsy; VEGF; VEGFR;
D O I
10.1196/annals.1413.021
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most cancerous lesions metastasize through the lymphatic system and the status of regional lymph nodes is the most important indicator of a patient's prognosis. The extent of lymph node involvement with cancer is also an important parameter used for determining treatment options. Although the importance of the lymphatic system for metastasis has been well recognized, traditionally, the lymphatic vessels have not been considered actively involved in the metastatic process. Recent evidence, however, indicates that the activation of the lymphatic system is an important factor in tumor progression to metastasis. Tumor lymphangiogenesis has been associated with increased propensity for metastasis, and lymphatic vessel density has emerged as another promising prognostic indicator. More recently, lymphangiogenesis in the sentinel lymph nodes has been shown to contribute to malignant progression. In addition to its role as a transport system for tumor cells, the lymphatic system may also be more actively involved in metastases by directly facilitating tumor cell recruitment into the lymphatic vessels. This review highlights recent advances in our understanding of the mechanisms by which lymphatic vessels participate in metastasis.
引用
收藏
页码:235 / 241
页数:7
相关论文
共 84 条
  • [1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    Achen, MG
    Jeltsch, M
    Kukk, E
    Mäkinen, T
    Vitali, A
    Wilks, AF
    Alitalo, K
    Stacker, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
  • [2] B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization
    Angeli, V
    Ginhoux, F
    Llodrá, J
    Quemeneur, L
    Frenette, PS
    Skobe, M
    Jessberger, R
    Merad, M
    Randolph, GJ
    [J]. IMMUNITY, 2006, 24 (02) : 203 - 215
  • [4] Sentinel lymph node biopsy in colon cancer -: A prospective multicerlter trial
    Bembenek, Andreas E.
    Rosenberg, Robert
    Wagler, Elke
    Gretschel, Stephan
    Sendler, Andreas
    Siewert, Joerg-Ruediger
    Naehrig, Joerg
    Witzigmann, Helmut
    Hauss, Johann
    Knorr, Christian
    Dimmler, Arno
    Groene, Joern
    Buhr, Heinz-Johannes
    Haier, Joerg
    Herbst, Hermann
    Tepel, Juergen
    Siphos, Bence
    Kleespies, Axel
    Koenigsrainer, Alfred
    Stoecklein, Nikolas H.
    Horstmann, Olaf
    Gruetzmann, Robert
    Imdahl, Andreas
    Svoboda, Daniel
    Wittekind, Christian
    Schneider, Wolfgang
    Wernecke, Klaus-Dieter
    Schlag, Peter M.
    [J]. ANNALS OF SURGERY, 2007, 245 (06) : 858 - 863
  • [5] Local excision and postoperative radiotherapy for distal rectal cancer
    Benson, R
    Wong, CS
    Cummings, BJ
    Brierley, J
    Catton, P
    Ringash, J
    Abdolell, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (05): : 1309 - 1316
  • [6] Opinion - Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
    Cao, YH
    [J]. NATURE REVIEWS CANCER, 2005, 5 (09) : 735 - 743
  • [7] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [8] Lymphatic vessel activation in cancer
    Cassella, M
    Skobe, M
    [J]. LYMPHATIC CONTINUUM: LYMPHATIC BIOLOGY AND DISEASE, 2002, 979 : 120 - 130
  • [9] Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma
    Cheng, L
    Jones, TD
    Lin, HQ
    Eble, JN
    Zeng, G
    Carr, MD
    Koch, MO
    [J]. JOURNAL OF UROLOGY, 2005, 174 (06) : 2181 - 2185
  • [10] Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO